Table 5.

Phase II and III clinical trials studying Jak inhibitors in alopecia areata and vitiligo.

Disease	Drug name	Identifier	Status	Phase, administration	Enrollment	Duration
Alopecia areata	Baricitinib	NCT03570749	Ongoing	II/III, per os	725	36-week
	PF-06651600 and PF-06700841	NCT02974868	Ongoing	IIa, per os	142	24-week with extension period up to 2 years
	Delgocitinib	NCT02561585	Results submitted	II, topical	31	12-week
Vitiligo	Ruxolitinib	NCT03099304	Ongoing	II, topical	157	1-year with 1 year open-label extension
	PF-06651600 and PF06700841	NCT03715829	Recruiting	IIb, per os	330	60-week with 24 weeks dose ranging and 24 week extension period